Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Equity Average (2019 - 2025)

Benitec Biopharma has reported Equity Average over the past 7 years, most recently at $140.5 million for Q4 2025.

  • Quarterly results put Equity Average at $140.5 million for Q4 2025, up 243.85% from a year ago — trailing twelve months through Dec 2025 was $140.5 million (up 243.85% YoY), and the annual figure for FY2025 was $72.3 million, up 204.62%.
  • Equity Average reached $140.5 million in Q4 2025 per BNTC's latest filing, up from $95.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $140.5 million in Q4 2025 and bottomed at -$109.7 million in Q1 2025.
  • Median Equity Average over the past 5 years was $11.5 million (2022), compared with a mean of $3.5 million.
  • The largest annual shift saw Equity Average soared 1095.28% in 2024 before it tumbled 913.39% in 2025.
  • Over 5 years, Equity Average stood at $13.2 million in 2021, then decreased by 10.28% to $11.8 million in 2022, then soared by 60.03% to $18.9 million in 2023, then crashed by 617.01% to -$97.7 million in 2024, then surged by 243.85% to $140.5 million in 2025.
  • Business Quant data shows Equity Average for BNTC at $140.5 million in Q4 2025, $95.4 million in Q3 2025, and -$61.0 million in Q2 2025.